Clinical trial
Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin…
NCT00254904 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00254904 |
|---|---|
| Title | Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC |
| Official title | International, Randomized, Open-Label, Phase 3 Trial of Gemcitabine/Cisplatin Plus PF-3512676 Versus Gemcitabine/Cisplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | Cisplatin, Gemcitabine, PF-3512676, Gemcitabine + Cisplatin |
| Enrollment | 839 |
| Start date | Nov 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Nov 17, 2005 |
| Last update posted | Mar 30, 2015 |
| Countries | Austria, Belgium, Brazil, Canada, China, Czechia, Germany, Hong Kong, Hungary, India, Israel, Italy and 12 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: